title: TLR4 signaling: a potential therapeutic target in ischemic coronary artery disease.
abstract: Atherosclerosis has been widely considered as a chronic inflammation process, which triggers a wide range of cardiovascular diseases such as ischemic coronary artery disease (CAD). Toll-like receptor 4 (TLR4), a primary receptor of the innate immune system, plays a pivotal role in the initiation and progression of atherosclerosis. Here we summarize recent progress on understanding the activation and function of TLR4 signaling in the initiation and development of CAD, with the focus on the role of TLR4 as a link between CAD and other inflammatory diseases. Furthermore, we list a variety of drugs which exert anti-atherosclerosis effects via targeting TLR4 signaling. Finally, we discuss the promise of TLR4 signaling as a therapeutic target for CAD.
authors.affiliation: Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha 410011, China; Department of Pharmaceutics, The Third Xiangya Hospital, Central South University, Changsha 410013, China.
authors.forename: Su-Jie
authors.initials: SJ
authors.lastname: Jia
authors.affiliation: Department of Pharmaceutics, The Third Xiangya Hospital, Central South University, Changsha 410013, China.
authors.forename: Pan-Pan
authors.initials: PP
authors.lastname: Niu
authors.affiliation: Department of Pharmaceutics, Hongqi Hospital of Mudanjiang Medical College, Mudanjiang 157000, China.
authors.forename: Jun-Zi
authors.initials: JZ
authors.lastname: Cong
authors.affiliation: Department of Pharmaceutics, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Bi-Kui
authors.initials: BK
authors.lastname: Zhang
authors.affiliation: Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha 410011, China. Electronic address: zhaoming6260@gmail.com.
authors.forename: Ming
authors.initials: M
authors.lastname: Zhao
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000276:immunology / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007113:Immunity, Innate / Q000187:drug effects; D058990:Molecular Targeted Therapy; D012084:Renin-Angiotensin System / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D051197:Toll-Like Receptor 4 / Q000037:antagonists & inhibitors / Q000276:immunology*
chemical_list: D000893:Anti-Inflammatory Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D051197:Toll-Like Receptor 4
keywords: Atherosclerosis; Coronary artery disease; Inflammation; TLR4; ox-LDL